Aurobindo Pharma Limited · NSE: AUROPHARMA · BSE: 524804
Aurobindo Pharma
Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 05 Aug 2026.
Q1 FY27 · Consolidated
Revenue
9,150.35₹ Cr
+16.3% vs year ago
Net profit
1,032.03₹ Cr
+25.2% vs year ago
EPS, basic
17.86₹
+25.8% vs year ago
Net margin
11.3%
+0.8 pts vs year ago
Quarter by quarter
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 9,150.35 | +16.3% | 1,032.03 | +25.2% | 17.86 | 05 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 8,853.34 | +5.6% | 920.84 | +2.0% | 15.86 | 21 May 2026 |
| Q3 FY26Oct–Dec 2025 | 8,645.90 | +8.4% | 909.80 | +7.6% | 15.67 | 09 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 8,285.70 | +6.3% | 848.13 | +3.8% | 14.61 | 05 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 7,868.14 | +4.0% | 824.20 | −10.2% | 14.20 | 04 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 8,382.12 | +10.6% | 902.83 | −0.5% | 15.56 | 26 May 2025 |
| Q3 FY25Oct–Dec 2024 | 7,978.52 | +8.5% | 845.57 | −10.0% | 14.56 | 06 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 7,796.07 | +8.0% | 816.95 | +8.6% | 14.00 | 09 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 7,567.02 | +10.5% | 918.22 | +61.2% | 15.69 | 13 Aug 2024 |
| Q4 FY24Jan–Mar 2024 | 7,580.15 | +17.1% | 907.35 | +79.4% | 15.51 | 27 May 2024 |
| Q3 FY24Oct–Dec 2023 | 7,351.78 | +14.7% | 939.97 | +91.4% | 16.04 | 12 Feb 2024 |
| Q2 FY24Jul–Sep 2023 | 7,219.42 | +25.8% | 751.94 | +83.2% | 12.83 | 13 Nov 2023 |
| Q1 FY24Apr–Jun 2023 | 6,850.52 | +9.9% | 569.71 | +9.5% | 9.74 | 12 Aug 2023 |
| Q4 FY23Jan–Mar 2023 | 6,472.96 | +11.4% | 505.91 | −12.2% | 8.64 | 27 May 2023 |
| Q3 FY23Oct–Dec 2022 | 6,407.13 | +6.7% | 491.01 | −18.7% | 8.38 | 10 Feb 2023 |
| Q2 FY23Jul–Sep 2022 | 5,739.37 | −3.4% | 410.37 | −41.1% | 6.99 | 13 Nov 2022 |
| Q1 FY23Apr–Jun 2022 | 6,235.92 | +9.4% | 520.38 | −32.4% | 8.88 | 13 Aug 2022 |
| Q4 FY22Jan–Mar 2022 | 5,809.37 | −3.2% | 576.14 | −28.1% | 9.84 | 31 May 2022 |
| Q3 FY22Oct–Dec 2021 | 6,002.22 | −5.7% | 604.29 | −79.5% | 10.32 | 10 Feb 2022 |
| Q2 FY22Jul–Sep 2021 | 5,941.92 | −8.4% | 696.71 | −13.5% | 11.89 | 09 Nov 2021 |
| Q1 FY22Apr–Jun 2021 | 5,701.98 | −3.8% | 769.97 | −1.4% | 13.14 | 13 Aug 2021 |
| Q4 FY21Jan–Mar 2021 | 6,001.50 | −2.5% | 801.18 | −5.6% | 13.67 | 31 May 2021 |
| Q3 FY21Oct–Dec 2020 | 6,364.91 | +8.0% | 2,946.32 | +317.7% | 50.29 | 11 Feb 2021 |
| Q2 FY21Jul–Sep 2020 | 6,483.44 | +15.8% | 805.65 | +26.0% | 13.75 | 12 Nov 2020 |
| Q1 FY21Apr–Jun 2020 | 5,924.78 | +8.8% | 780.68 | +22.8% | 13.32 | 13 Aug 2020 |
| Q4 FY20Jan–Mar 2020 | 6,158.43 | +16.4% | 848.99 | +45.1% | 14.50 | 04 Jun 2020 |
| Q3 FY20Oct–Dec 2019 | 5,895.00 | +11.9% | 705.31 | −1.0% | 12.04 | 07 Feb 2020 |
| Q2 FY20Jul–Sep 2019 | 5,600.47 | +17.9% | 639.53 | +4.6% | 10.92 | 13 Nov 2019 |
| Q1 FY20Apr–Jun 2019 | 5,444.60 | +28.1% | 635.68 | +39.5% | 10.85 | 08 Aug 2019 |
| Q4 FY19Jan–Mar 2019 | 5,292.20 | — | 585.22 | — | 9.99 | 29 May 2019 |
| Q3 FY19Oct–Dec 2018 | 5,269.67 | — | 712.21 | — | 12.15 | 08 Feb 2019 |
| Q2 FY19Jul–Sep 2018 | 4,751.40 | — | 611.44 | — | 10.44 | 13 Nov 2018 |
| Q1 FY19Apr–Jun 2018 | 4,250.27 | — | 455.59 | — | 7.78 | 10 Aug 2018 |
Standalone results
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 2,799.51 | −1.7% | 737.22 | +31.9% | 12.75 | 05 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 2,786.55 | +2.0% | 692.23 | +69.6% | 11.92 | 21 May 2026 |
| Q3 FY26Oct–Dec 2025 | 2,747.28 | −5.8% | 582.07 | +23.3% | 10.02 | 09 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 2,789.72 | −1.2% | 581.37 | +8.2% | 10.01 | 05 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 2,848.17 | +15.8% | 559.13 | +69.9% | 9.63 | 04 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 2,731.99 | −5.6% | 408.17 | −29.5% | 7.03 | 26 May 2025 |
| Q3 FY25Oct–Dec 2024 | 2,916.63 | +8.3% | 472.05 | −24.3% | 8.13 | 06 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 2,824.59 | +5.8% | 537.53 | +29.3% | 9.21 | 09 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 2,460.09 | +2.9% | 329.04 | −2.1% | 5.62 | 13 Aug 2024 |
| Q4 FY24Jan–Mar 2024 | 2,894.03 | −18.4% | 578.67 | −10.3% | 9.88 | 27 May 2024 |
| Q3 FY24Oct–Dec 2023 | 2,692.03 | −21.6% | 623.78 | +108.7% | 10.65 | 12 Feb 2024 |
| Q2 FY24Jul–Sep 2023 | 2,668.76 | −11.8% | 415.74 | +152.5% | 7.10 | 13 Nov 2023 |
| Q1 FY24Apr–Jun 2023 | 2,390.82 | −14.2% | 335.95 | +175.0% | 5.74 | 12 Aug 2023 |
| Q4 FY23Jan–Mar 2023 | 3,547.44 | +22.9% | 644.80 | −19.6% | 11.00 | 27 May 2023 |
| Q3 FY23Oct–Dec 2022 | 3,432.26 | +30.8% | 298.82 | +24.6% | 5.10 | 10 Feb 2023 |
| Q2 FY23Jul–Sep 2022 | 3,025.66 | +4.9% | 164.63 | −16.7% | 2.81 | 13 Nov 2022 |
| Q1 FY23Apr–Jun 2022 | 2,786.92 | −3.7% | 122.16 | −43.2% | 2.08 | 13 Aug 2022 |
| Q4 FY22Jan–Mar 2022 | 2,887.17 | −29.8% | 802.16 | −8.1% | 13.69 | 31 May 2022 |
| Q3 FY22Oct–Dec 2021 | 2,623.05 | −29.3% | 239.81 | −67.6% | 4.09 | 10 Feb 2022 |
| Q2 FY22Jul–Sep 2021 | 2,883.18 | −36.3% | 197.68 | −75.3% | 3.37 | 09 Nov 2021 |
| Q1 FY22Apr–Jun 2021 | 2,893.75 | −15.4% | 215.07 | −69.9% | 3.67 | 13 Aug 2021 |
| Q4 FY21Jan–Mar 2021 | 4,114.03 | +13.6% | 872.58 | +20.3% | 14.89 | 31 May 2021 |
| Q3 FY21Oct–Dec 2020 | 3,710.86 | +10.9% | 740.51 | +76.7% | 12.64 | 11 Feb 2021 |
| Q2 FY21Jul–Sep 2020 | 4,524.34 | +40.4% | 801.54 | +101.3% | 13.68 | 12 Nov 2020 |
| Q1 FY21Apr–Jun 2020 | 3,419.70 | +11.1% | 714.68 | +116.2% | 12.20 | 13 Aug 2020 |
| Q4 FY20Jan–Mar 2020 | 3,620.32 | +10.4% | 725.04 | +57.6% | 12.37 | 04 Jun 2020 |
| Q3 FY20Oct–Dec 2019 | 3,345.67 | +3.0% | 419.07 | −9.6% | 7.15 | 07 Feb 2020 |
| Q2 FY20Jul–Sep 2019 | 3,221.66 | +1.6% | 398.13 | +4.5% | 6.80 | 13 Nov 2019 |
| Q1 FY20Apr–Jun 2019 | 3,078.83 | +20.3% | 330.50 | +46.8% | 5.64 | 08 Aug 2019 |
| Q4 FY19Jan–Mar 2019 | 3,280.58 | — | 460.14 | — | 7.85 | 29 May 2019 |
| Q3 FY19Oct–Dec 2018 | 3,248.10 | — | 463.51 | — | 7.91 | 08 Feb 2019 |
| Q2 FY19Jul–Sep 2018 | 3,170.39 | — | 380.95 | — | 6.50 | 13 Nov 2018 |
| Q1 FY19Apr–Jun 2018 | 2,558.82 | — | 225.12 | — | 3.84 | 10 Aug 2018 |
66 filings on record for this company.